MedTrace Logo

Combretastatin A4 Phosphate in Patients With Neovascular Age-Related Macular Degeneration

NCT01570790 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 8

Last updated 2017-12-06

No results posted yet for this study

Summary

The purpose of the study is assess safety, bioactivity, and maximal tolerated dose of repeated weekly intravenous infusion of combretastatin A-4 phosphate (CA4P) in patients with neovascular age-related macular degeneration

Conditions

  • Combretastatin A4 Phosphate
  • Age-related Macular Degeneration
  • AMD
  • CNV
  • Choroidal Neovascularization

Interventions

DRUG

Combretastatin A-4 phosphate

27 mg/m2 CA4P IV infusion at baseline and every week for 4 doses

DRUG

Combretastatin A-4 Phosphate

36 mg/m2 CA4P IV infusion at baseline and every week for 4 doses

DRUG

Combretastatin A-4 Phosphate

45 mg/m2 CA4P IV infusion at baseline and every week for 4 doses

Sponsors & Collaborators

Principal Investigators

  • Quan D Nguyen, MD, MSc · Wilmer Eye Institute - Johns Hopkins University School of Medicine

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2003-05-31
Primary Completion
2005-06-30
Completion
2005-06-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01570790 on ClinicalTrials.gov